The increase in the proportion of patients who achieved an objective response from
the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent
with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic
breast cancer.
Source: www.thelancet.com